Vivos Therapeutics (Vivos Therapeutics) COGS-to-Revenue : 0.43 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics COGS-to-Revenue?

Vivos Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $1.48 Mil. Its Revenue for the three months ended in Mar. 2024 was $3.42 Mil.

Vivos Therapeutics's COGS to Revenue for the three months ended in Mar. 2024 was 0.43.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Vivos Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was 56.65%.

Vivos Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Vivos Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics COGS-to-Revenue Chart

Vivos Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.24

0.20

0.25

0.37

0.40

Vivos Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.39	0.38	0.43	0.40	0.43

Vivos Therapeutics COGS-to-Revenue Calculation

Vivos Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	5.53	/	13.801
	=	0.40

Vivos Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.482	/	3.419
	=	0.43

Vivos Therapeutics (NAS:VVOS) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Vivos Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1.482 / 3.419
	=	56.65 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Vivos Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos Therapeutics (Vivos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120

Website

https://www.vivos.com

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.

Executives

Ronald Kirk Huntsman	director, 10 percent owner, officer: Chairman & CEO	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman	officer: Chief Financial Officer	6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow	director	REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson	director	2 MUSICK, IRVINE CA 92618
Anja B Krammer	director	C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh	director, 10 percent owner, officer: Chief Medical Officer	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay	director	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green	director	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129